Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00984399 · ClinicalTrials.gov registry record · NA
Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT00984399: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00984399 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00984399, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to see if Vagifem® 10mcg is safe for women who have had breast cancer. Vagifem is an estrogen product. It is a tiny tablet that is inserted into the vagina. It relieves vaginal dryness. Women who have had breast cancer are usually told not to take estrogen. This is because estrogen use can lead to a breast cancer recurrence or a new primary breast cancer. It is unclear if the estrogen in Vagifem is only absorbed in the vagina. It may be absorbed into the blood stream for a short time and may cause a brief rise in your estrogen level. However, there is no clear evidence that this would cause any bad effects in patients with breast cancer. How much, if any, of these topical estrogens are absorbed through the vagina is not known. We also do not know what the impact is of low dose estrogen absorption on breast cancer outcomes. Also, the absorption should decrease as the mucus membranes are restored after estrogen exposure.
Interventions
- DRUG Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-09-22 |
| Est. Completion | 2024-05-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00984399
The ClinicalTrials.gov registry entry for NCT00984399 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist is the first listed.
NCT00984399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00984399 about?
NCT00984399 is a clinical study titled "Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen". The purpose of this study is to see if Vagifem® 10mcg is safe for women who have had breast cancer. Vagifem is an estrogen product. It is a tiny tablet that is inserted into the vagina. It relieves vaginal dryness. Women who have had breast cancer are usually told not to take estrogen. This is becau...
What is the current status of trial NCT00984399?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2009-09-22. Estimated completion is 2024-05-13.
What interventions are being tested in trial NCT00984399?
The interventions under investigation include: Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist (DRUG).
Who is sponsoring clinical trial NCT00984399?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.